罗格列酮治疗2型糖尿病疗效观察

目的：探讨罗格列酮治疗2型糖尿病的临床疗效和安全性。方法：2型糖尿病患者90例，按治疗前用药情况分为罗格列酮治疗组（R组），合用磺脲治疗组（B组），合用二甲双胍治疗组（A组），每组30例。R组先行饮食及运动治疗，A组及B组保持原药物剂量不变，然后3组均给予罗格列酮4mg，每d1次，空腹口服，共51周。治疗前后抽取患者静脉血，葡萄糖氧化酶法测空腹血糖（FBG）及餐后2h血糖（P2hBG）；测糖化血红蛋白；放免法测空腹胰岛素（FINS）；计算胰岛素敏感性指数（A）和胰岛素抵抗指数（R）。结果：治疗后3组患者FBG、P2hBG、糖化血红蛋白、FINS水平及R值均较治疗前下降，A升高。上述各指标治疗前后的变化3组间比较差异无统计学意义（P〉0．05）。3组均未发生严重不良反应。结论：罗格列酮可单用或与二甲双胍、磺脲类合用，治疗2型糖尿病安全、有效。

Efficacy of rosiglitazone on treating Type 2 diabetes

Aim: To observe the efficacy of rosiglitazone on treating Type 2 diabetes.Methods: A total of 90 patients with Type 2 diabetes were allocated into 3 groups,30 in each group.Group R (which were treated with rosiglitazone) accepted diet control and had physical exercises,group A treated with sulfonylurea and group B treated with metformin before maintained the former administration. Then the 3 groups were all administrated rosiglitazone at a dose of 4 mg, 1 time per day for 51 weeks. Fasting blood glucose(FBG),P2hBG,saccharification hemoglobin(HbAli),and fasting insuline(FINS) were determined before and after therapy,and resistance index(R) and sensitivity index(A) to insulin were calculated.Results: FBG,P2hBG,HbAli,FINS,and R were decreased,and A was increased significantly in 3 groups of the pationts after treating with rosiglitazone.Conclusion: Rosiglitazone,or combined with sulfonylurea or metformin,is effective and safe in treatment of Type 2 diabetes.